Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN files for Orphan Designation for Ifenprodil on IPF
View:
Post by StockHawk1 on Nov 03, 2022 5:19pm

AGN files for Orphan Designation for Ifenprodil on IPF

Algernon Pharmaceuticals (AGN.c AGNPF) recently advanced its investigation of Ifenprodil for the treatment of the chronic lung condition IPF by filing a request to the FDA for Orphan Designation for this use of the drug. 


AGN's recent Ifenprodil study found it lessened the frequency of patients' IPF-associated cough, so there is a solid basis to believe this drug could be commercialized for the treatment of IPF. 


IMO receiving this Orphan Designation could be an upcoming catalyst for AGN to look out for


AGN @ $2.54, MC $6.034M

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-files-orphan-designation-110000532.html

 
Be the first to comment on this post
Algernon Pharmaceuticals Inc.